dpp4i and glp 1 agonist DPP-4 inhibitors GLP-1RAs: cardiovascular safety and benefits | Military Medical Research Comparison of GLP-1 receptor agonists

Back Marso, SP, Daniels, GH, Brown-Frandsen, K, et al (28 July 2016) 'Liraglutide and cardiovascular outcomes in type 2 diabetes', New England Journal of Medicine , 375/4, 311-22

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Further investigation is also needed in specific patient populations

GLP-1RA may thus confer benefits when used in individuals with established cardiovascular disease (mainly on atherosclerotic basis) or chronic kidney disease who accept injections

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: Systematic review and meta-analysis

However, an increase in gastrointestinal adverse events, diarrhea, hypoglycemia, nausea, neoplasm, treatment-emergent adverse events, pancreatic enzymes, diabetic retinopathy complications, and pancreatic cancer was observed to accompany the treatment using semaglutide